180 related articles for article (PubMed ID: 29792703)
1. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
2. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2).
Masamrekh R; Filippova T; Haurychenka Y; Shcherbakov K; Veselovsky A; Strushkevich N; Shkel T; Gilep A; Usanov S; Shumyantseva V; Kuzikov A
Steroids; 2020 Feb; 154():108528. PubMed ID: 31678135
[TBL] [Abstract][Full Text] [Related]
4. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
5. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
6. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5.
Estrada DF; Skinner AL; Laurence JS; Scott EE
J Biol Chem; 2014 May; 289(20):14310-20. PubMed ID: 24671419
[TBL] [Abstract][Full Text] [Related]
8. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
9. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
Masamrekh R; Kuzikov A; Veselovsky A; Toropygin I; Shkel T; Strushkevich N; Gilep A; Usanov S; Archakov A; Shumyantseva V
J Inorg Biochem; 2018 Sep; 186():24-33. PubMed ID: 29807244
[TBL] [Abstract][Full Text] [Related]
10. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
11. Conformational selection dominates binding of steroids to human cytochrome P450 17A1.
Guengerich FP; Wilkey CJ; Glass SM; Reddish MJ
J Biol Chem; 2019 Jun; 294(26):10028-10041. PubMed ID: 31072872
[TBL] [Abstract][Full Text] [Related]
12. Structural and kinetic basis of steroid 17α,20-lyase activity in teleost fish cytochrome P450 17A1 and its absence in cytochrome P450 17A2.
Pallan PS; Nagy LD; Lei L; Gonzalez E; Kramlinger VM; Azumaya CM; Wawrzak Z; Waterman MR; Guengerich FP; Egli M
J Biol Chem; 2015 Feb; 290(6):3248-68. PubMed ID: 25533464
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z
J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
[TBL] [Abstract][Full Text] [Related]
14. Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR.
Estrada DF; Laurence JS; Scott EE
J Biol Chem; 2013 Jun; 288(23):17008-17018. PubMed ID: 23620596
[TBL] [Abstract][Full Text] [Related]
15. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
Dhir V; Ivison HE; Krone N; Shackleton CH; Doherty AJ; Stewart PM; Arlt W
Mol Endocrinol; 2007 Aug; 21(8):1958-68. PubMed ID: 17505056
[TBL] [Abstract][Full Text] [Related]
17. [Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1].
Stulov SV; Dugin NO; Zharkova MS; Shcherbinin DS; Kuzikov AV; Shumyantseva VV; Misharin AY; Veselovsky AV
Biomed Khim; 2016; 62(1):38-44. PubMed ID: 26973185
[TBL] [Abstract][Full Text] [Related]
18. New CYP17 hydroxylase inhibitors: synthesis, biological evaluation, QSAR, and molecular docking study of new pregnenolone analogs.
Al-Masoudi NA; Ali DS; Saeed B; Hartmann RW; Engel M; Rashid S; Saeed A
Arch Pharm (Weinheim); 2014 Dec; 347(12):896-907. PubMed ID: 25251696
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
20. Modified bile acids and androstanes-Novel promising inhibitors of human cytochrome P450 17A1.
Dzichenka Y; Shapira M; Yantsevich A; Cherkesova T; Grbović L; Savić M; Usanov S; Jovanović-Šanta S
J Steroid Biochem Mol Biol; 2021 Jan; 205():105777. PubMed ID: 33157220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
